Reports

Hub Group delivered strong operating cash flows and revenue performance in 2025 despite industry headwinds, supported by intermodal volume growth and new business awards. The company announced a delay in its full earnings release and conference call due to an error in financial statements for the first, second, and third quarters of 2025, which resulted in an understatement of purchased transportation costs and accounts payable.

• Fourth quarter intermodal volume increased 1% from the prior year.
• Strong year-end balance sheet with cash and restricted cash of approximately $140 million and lower net debt.

Atara Biotherapeutics has renegotiated a $9.0 million milestone payment to HealthCare Royalty (HCRx), extending the due date from June 2026 to January 2028. This move is intended to provide the company with greater financial flexibility as it addresses FDA concerns regarding tabelecleucel (tab-cel) following a recent Complete Response Letter (CRL).

• Renegotiated a $9.0 million one-time milestone payment due date with HCRx, extending it to January 1, 2028.
• Issued a warrant to HCRx for the purchase of up to 400,000 shares of common stock at an exercise price of $0.0001 per share.